Premier Alternatives

ClostraBio

Chicago, IL · Founded 2016 · Privately Held (backing)

Developer of biopharmaceuticals intended to offer therapeutics for food allergies. ClostraBio is based in Chicago, IL and was founded in 2016. It was valued at $16 million at its later-stage round in Sep 2022, the last priced event on record. It has raised $14.2 million across 1 recorded round; the latest was a $9.9 million early-stage round in Sep 2022.

PMV mark · valuation
$16.0M
Oct 2026
Priced at
its later-stage round
Sep 2022
Total raised
$14.2M
Last round
Early Stage VC
Sep 2022

ClostraBio key facts

as of Oct 2026
  • Developer of biopharmaceuticals intended to offer therapeutics for food allergies.
  • ClostraBio is valued at approximately $16.0M as of Oct 2026, set at its later-stage round, Sep 2022; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $14.2M across 1 recorded rounds; the latest was Early Stage VC ($9.9M) in Sep 2022.
  • Notable investors include Polsky Center for Entrepreneurship and Innovation at the University of Chicago, Mansueto Office, Angela Oakey, Daniel Oakey, New Venture Challenge — 10 tracked in total.
  • ClostraBio has filed 1 Form D with the SEC, most recently Sep 2022 ($9.9M sold to 15 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$16.0M

Valued at $16.0M at its later-stage round, Sep 2022. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of ClostraBio with a free account
  • ·Watch ClostraBio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

ClostraBio funding rounds

1 rounds
Sep 2022Early Stage VC$9.9MSEC filing▮
Full funding history →

ClostraBio valuation

ClostraBio was valued at $16 million at its later-stage round in Sep 2022. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has ClostraBio raised?

ClostraBio has raised $14.2 million in total; 1 of its rounds is on record. The largest on record was a $9.9 million early-stage round in Sep 2022.

ClostraBio has filed 1 Form D with the SEC, most recently in Sep 2022 ($9.9 million sold to 15 investors).

ClostraBio investors

10 investors are on record for ClostraBio, including Polsky Center for Entrepreneurship and Innovation at the University of Chicago, Mansueto Office, Angela Oakey and Daniel Oakey. The early-stage round in Sep 2022 drew 15 investors.

About ClostraBio

Developer of biopharmaceuticals intended to offer therapeutics for food allergies. The company's technology specializes in developing microbiome-modulating therapeutics and commercializing small-molecule formulations as well as dietary fibers that modulate the gut microbiome to confer protection against food antigens, enabling doctors to treat patients suffering from life-threatening food allergies effectively.

Sector
Healthcare
HQ
Chicago, IL, United States
Founded
2016
Employees
9
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.